At the beginning of this year, pegzilarginase, a recombinant, cobalt-substituted, and pegylated human ARG1 enzyme therapy, received approval as an orphan drug in the European Union for the treatment of Arg1 deficiency (Russo et al, 2024). Here, ARG1 is linked to hyperinsulinemic hypoglycemia, familial, 4.